EUVIMEDEUVIMED entdecken
Crossref

Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine

John Cookson, Jonathan Pimm

BJPsych Advances · 2023-03 · 29 (2) · 145-150

DOI: 10.1192/bja.2021.49 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJPsych Advances, online erschienen am 02.09.2021. Verfasst von John Cookson und 1 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aripiprazole, brexpiprazole and cariprazine are partial dopamine (and serotonin) agonists developed as novel antipsychotics. This article discusses their pharmacology, evidence on their licensed and off-licence uses (including psychosis, mania, bipolar depression, Tourette syndrome and autism spectrum disorder) and side-effects. In schizophrenia, they have a low risk of Parkinsonism or hyperprolactinaemia, cause modest increases in body weight and are of moderate efficacy.

Zitieren

APA

Cookson, J., & Pimm, J. (2023). Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances, 29(2), 145-150. https://doi.org/10.1192/bja.2021.49

Vancouver

Cookson J, Pimm J. Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances. 2023;29(2):145-150. doi:10.1192/bja.2021.49

BibTeX
@article{Cookson2023,
  author = {Cookson, John and Pimm, Jonathan},
  title = {Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine},
  journal = {BJPsych Advances},
  year = {2023},
  volume = {29},
  number = {2},
  pages = {145--150},
  doi = {10.1192/bja.2021.49}
}
Kostenlos starten →